Literature DB >> 7789952

Recurrence of osteogenesis imperfecta because of paternal mosaicism: Gly862-->Ser substitution in a type I collagen gene (COL1A1).

C Namikawa1, K Suzumori, Y Fukushima, M Sasaki, A Hata.   

Abstract

We determined that two siblings with type III osteogenesis imperfecta (OI) had the same single base substitution that converted the codon for glycine (Gly) 862 to a codon for serine (Ser) in exon 44 of the alpha 1 chain of the type I (alpha 1(I)) collagen gene (COL1A1). The mutation was also detected in various paternal tissues; the mutant allele accounted for approximately 11% of the COL1A1 alleles in blood, 24% of those in fibroblasts, and 43% of those in sperm determined by allele-specific colony hybridization using amplified genomic sequences. These findings demonstrate that germ-line mosaicism in the phenotypically normal father is responsible for the recurrence. There is a cluster of serine substitutions for Gly (Gly832, Gly844 and Gly901) which is associated with nonlethal phenotypes and which is located between two lethal clusters. In the cases studied here, a Gly862-->Ser mutation was identified that is located inside the nonlethal cluster.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7789952     DOI: 10.1007/bf00209484

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  19 in total

1.  A dominant mutation in the COL1A1 gene that substitutes glycine for valine causes recurrent lethal osteogenesis imperfecta.

Authors:  J Bonaventure; L Cohen-Solal; C Lasselin; P Maroteaux
Journal:  Hum Genet       Date:  1992-08       Impact factor: 4.132

Review 2.  Brittle bones--fragile molecules: disorders of collagen gene structure and expression.

Authors:  P H Byers
Journal:  Trends Genet       Date:  1990-09       Impact factor: 11.639

3.  Mutations that substitute serine for glycine alpha 1-598 and glycine alpha 1-631 in type I procollagen. The effects on thermal unfolding of the triple helix are position-specific and demonstrate that the protein unfolds through a series of cooperative blocks.

Authors:  A Westerhausen; J Kishi; D J Prockop
Journal:  J Biol Chem       Date:  1990-08-15       Impact factor: 5.157

Review 4.  Review and hypotheses: somatic mosaicism: observations related to clinical genetics.

Authors:  J G Hall
Journal:  Am J Hum Genet       Date:  1988-10       Impact factor: 11.025

5.  Variable expression of osteogenesis imperfecta in a nuclear family is explained by somatic mosaicism for a lethal point mutation in the alpha 1(I) gene (COL1A1) of type I collagen in a parent.

Authors:  G A Wallis; B J Starman; A B Zinn; P H Byers
Journal:  Am J Hum Genet       Date:  1990-06       Impact factor: 11.025

6.  Phenotypic heterogeneity in osteogenesis imperfecta: the mildly affected mother of a proband with a lethal variant has the same mutation substituting cysteine for alpha 1-glycine 904 in a type I procollagen gene (COL1A1).

Authors:  C D Constantinou; M Pack; S B Young; D J Prockop
Journal:  Am J Hum Genet       Date:  1990-10       Impact factor: 11.025

7.  Mild dominant osteogenesis imperfecta with intrafamilial variability: the cause is a serine for glycine alpha 1(I) 901 substitution in a type-I collagen gene.

Authors:  M Mottes; A Sangalli; M Valli; M Gomez Lira; R Tenni; P Buttitta; P F Pignatti; G Cetta
Journal:  Hum Genet       Date:  1992-07       Impact factor: 4.132

8.  Recurrence of lethal osteogenesis imperfecta due to parental mosaicism for a mutation in the COL1A2 gene of type I collagen. The mosaic parent exhibits phenotypic features of a mild form of the disease.

Authors:  M J Edwards; R J Wenstrup; P H Byers; D H Cohn
Journal:  Hum Mutat       Date:  1992       Impact factor: 4.878

9.  Perinatal lethal osteogenesis imperfecta in transgenic mice bearing an engineered mutant pro-alpha 1(I) collagen gene.

Authors:  A Stacey; J Bateman; T Choi; T Mascara; W Cole; R Jaenisch
Journal:  Nature       Date:  1988-03-10       Impact factor: 49.962

10.  Characterization of three osteogenesis imperfecta collagen alpha 1(I) glycine to serine mutations demonstrating a position-dependent gradient of phenotypic severity.

Authors:  J F Bateman; I Moeller; M Hannagan; D Chan; W G Cole
Journal:  Biochem J       Date:  1992-11-15       Impact factor: 3.857

View more
  7 in total

1.  MECP2 mutations in sporadic cases of Rett syndrome are almost exclusively of paternal origin.

Authors:  R Trappe; F Laccone; J Cobilanschi; M Meins; P Huppke; F Hanefeld; W Engel
Journal:  Am J Hum Genet       Date:  2001-04-17       Impact factor: 11.025

Review 2.  A perspective on the evolution of germ-cell development and germinal mosaics of deleterious mutations.

Authors:  Ronny C Woodruff; Michael A Balinski; Juan L Bouzat
Journal:  Genetica       Date:  2015-06-26       Impact factor: 1.082

3.  Evidence for a de novo, dominant germ-line mutation causative of osteogenesis imperfecta in two Red Angus calves.

Authors:  Jessica L Petersen; Shauna M Tietze; Rachel M Burrack; David J Steffen
Journal:  Mamm Genome       Date:  2019-02-20       Impact factor: 2.957

4.  Two novel COL1A1 mutations in patients with osteogenesis imperfecta (OI) affect the stability of the collagen type I triple-helix.

Authors:  Joanna Witecka; Aleksandra M Auguściak-Duma; Anna Kruczek; Anna Szydło; Marta Lesiak; Maria Krzak; Jacek J Pietrzyk; Minna Männikkö; Aleksander L Sieroń
Journal:  J Appl Genet       Date:  2008       Impact factor: 3.240

Review 5.  Genetic mosaics and the germ line lineage.

Authors:  Mark E Samuels; Jan M Friedman
Journal:  Genes (Basel)       Date:  2015-04-17       Impact factor: 4.096

6.  Asymptomatic parental mosaicism for osteogenesis imperfecta associated with a new splice site mutation in COL1A2.

Authors:  Anja Lisbeth Frederiksen; Morten Duno; Iben B G Johnsen; Morten Frost Nielsen; Anne Bruun Krøigård
Journal:  Clin Case Rep       Date:  2016-08-31

Review 7.  Sperm mosaicism: implications for genomic diversity and disease.

Authors:  Martin W Breuss; Xiaoxu Yang; Joseph G Gleeson
Journal:  Trends Genet       Date:  2021-06-19       Impact factor: 11.821

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.